NCT05757544View on ClinicalTrials.gov

Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 1, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Status Epilepticus
Interventions
DRUG

IV Ganaxolone

IV Ganaxolone will be administered.

DRUG

IV Placebo

IV Placebo will be administered

Sponsors
All Listed Sponsors
lead

Marinus Pharmaceuticals

INDUSTRY

NCT05757544 - Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE) | Biotech Hunter | Biotech Hunter